A Study of GLB-001 in Patients With Myeloid Malignancies

Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), lower-risk myelodysplastic syndrome (LR-MDS), higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML). This study consists of 3 parts, dose escalation (Phase 1a), dose exploration (Phase 1b) and dose expansion (Phase 1c). Dose e

Trial Details

NCT ID
NCT06378437
Phase
PHASE1
Sponsor
Hangzhou GluBio Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • GLB-001
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Shijiazhuang, Hebei, China|38.04139,114.47861
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Study participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures bei…
  • Study participants is ≥18 years of age at the time of signing the ICF.
  • Study participants with confirmed diagnosis of relapsed or refractory or intolerant myeloid malignancies including PV, ET, primary myelofibrosis (P…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →